Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea

Published:2014 Issue:4 Volume:29 Page:494
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Baik Young Ok¹^ORCID,Choi Seuk Keun¹^ORCID,Kim Jae Woo²^ORCID,Yang Jae Seung³^ORCID,Kim Ick Young⁴^ORCID,Kim Chan Wha⁴,Hong Jang Hee²

Affiliation:

1. EuBiologics Co., Ltd., Chuncheon, Korea.

2. Department of Pharmacology and Clinical Trials Center, Chungnam National University, College of Medicine and Hospital, Daejeon, Korea.

3. Clinical Immunology Section, International Vaccine Institute (IVI), Seoul, Korea.

4. Department of Biotechnology, Korea University, Seoul, Korea.

Funder

Gangwon Institute for Regional Program Evaluation, Ministry of Trade, Industry and Administration, Korea

Korea Healthcare technology R&D Project (Korea National Enterprise for Clinical Trial), Ministry of Health & Welfare, Korea

Publisher

Korean Academy of Medical Sciences

Subject

General Medicine

Link

https://synapse.koreamed.org/pdf/10.3346/jkms.2014.29.4.494

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia;Vaccine;2024-08

2. Antibacterial carbonic anhydrase inhibitors targeting Vibrio cholerae enzymes;Expert Opinion on Therapeutic Targets;2024-07-02

3. Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti;International Journal of Infectious Diseases;2024-02

4. Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial;The Lancet Regional Health - Southeast Asia;2023-12

5. Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges;The Lancet Infectious Diseases;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3